5-Fluorouracil with leucovorin in breast cancer

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Extensive preclinical data have demonstrated that leucovorin can modulate 5-fluorouracil (5-FU) cytotoxicity. Additionally, randomized clinical trials have shown that leucovorin increases the therapeutic index of 5-FU in patients with advanced colorectal cancer, setting a new therapeutic standard for this disease. Based on this information, several controlled, but nonrandomized, clinical trials have examined the combination of 5-FU and leucovorin in patients with metastatic breast cancer. Although many of these trials are still ongoing, preliminary information suggests that leucovorin also potentiates 5-FU activity against breast carcinoma. However, to date, it has not been shown that leucovorin increases the therapeutic index of 5-FU in these patients. Continued testing of the role of leucovorin in combination chemotherapy for breast cancer appears warranted.

Original languageEnglish (US)
Pages (from-to)1045-1047
Number of pages3
JournalCancer
Volume63
Issue number6 SUPPL.
StatePublished - 1989

Fingerprint

Leucovorin
Fluorouracil
Breast Neoplasms
Combination Drug Therapy
Colorectal Neoplasms
Therapeutics
Randomized Controlled Trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

5-Fluorouracil with leucovorin in breast cancer. / Loprinzi, Charles Lawrence.

In: Cancer, Vol. 63, No. 6 SUPPL., 1989, p. 1045-1047.

Research output: Contribution to journalArticle

Loprinzi, CL 1989, '5-Fluorouracil with leucovorin in breast cancer', Cancer, vol. 63, no. 6 SUPPL., pp. 1045-1047.
Loprinzi, Charles Lawrence. / 5-Fluorouracil with leucovorin in breast cancer. In: Cancer. 1989 ; Vol. 63, No. 6 SUPPL. pp. 1045-1047.
@article{123d2a18e11e4daf805d6c696ba6ce42,
title = "5-Fluorouracil with leucovorin in breast cancer",
abstract = "Extensive preclinical data have demonstrated that leucovorin can modulate 5-fluorouracil (5-FU) cytotoxicity. Additionally, randomized clinical trials have shown that leucovorin increases the therapeutic index of 5-FU in patients with advanced colorectal cancer, setting a new therapeutic standard for this disease. Based on this information, several controlled, but nonrandomized, clinical trials have examined the combination of 5-FU and leucovorin in patients with metastatic breast cancer. Although many of these trials are still ongoing, preliminary information suggests that leucovorin also potentiates 5-FU activity against breast carcinoma. However, to date, it has not been shown that leucovorin increases the therapeutic index of 5-FU in these patients. Continued testing of the role of leucovorin in combination chemotherapy for breast cancer appears warranted.",
author = "Loprinzi, {Charles Lawrence}",
year = "1989",
language = "English (US)",
volume = "63",
pages = "1045--1047",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6 SUPPL.",

}

TY - JOUR

T1 - 5-Fluorouracil with leucovorin in breast cancer

AU - Loprinzi, Charles Lawrence

PY - 1989

Y1 - 1989

N2 - Extensive preclinical data have demonstrated that leucovorin can modulate 5-fluorouracil (5-FU) cytotoxicity. Additionally, randomized clinical trials have shown that leucovorin increases the therapeutic index of 5-FU in patients with advanced colorectal cancer, setting a new therapeutic standard for this disease. Based on this information, several controlled, but nonrandomized, clinical trials have examined the combination of 5-FU and leucovorin in patients with metastatic breast cancer. Although many of these trials are still ongoing, preliminary information suggests that leucovorin also potentiates 5-FU activity against breast carcinoma. However, to date, it has not been shown that leucovorin increases the therapeutic index of 5-FU in these patients. Continued testing of the role of leucovorin in combination chemotherapy for breast cancer appears warranted.

AB - Extensive preclinical data have demonstrated that leucovorin can modulate 5-fluorouracil (5-FU) cytotoxicity. Additionally, randomized clinical trials have shown that leucovorin increases the therapeutic index of 5-FU in patients with advanced colorectal cancer, setting a new therapeutic standard for this disease. Based on this information, several controlled, but nonrandomized, clinical trials have examined the combination of 5-FU and leucovorin in patients with metastatic breast cancer. Although many of these trials are still ongoing, preliminary information suggests that leucovorin also potentiates 5-FU activity against breast carcinoma. However, to date, it has not been shown that leucovorin increases the therapeutic index of 5-FU in these patients. Continued testing of the role of leucovorin in combination chemotherapy for breast cancer appears warranted.

UR - http://www.scopus.com/inward/record.url?scp=0024521502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024521502&partnerID=8YFLogxK

M3 - Article

C2 - 2645043

AN - SCOPUS:0024521502

VL - 63

SP - 1045

EP - 1047

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6 SUPPL.

ER -